Abstract | BACKGROUND: METHODS: A retrospective analysis of baseline clinico-pathological presentation and treatment-outcome was performed among 11 paediatric MPA patients. All of whom were treated with a pre-specified cyclophosphamide free, rituximab- and mycophenolate mofetil (MMF)-based management protocol as per centre practice. RESULTS: We describe the clinical course of 11 children with MPA over a median follow-up period of 20.9 months. Both patient survival and renal survival at 1 year follow-up were 100%. In spite of the varying degree of renal involvement at presentation, kidney function was recovered in all patients with a median estimated glomerular filtration rate (eGFR) of 79.5 mL/min/1.73 m(2). At last follow-up, 91% (10/11) of patients were in complete remission and one (9%) child continued partial remission state. There was no treatment failure. In total, 73% (8/11) of patients were off steroids at last follow-up and 82% (9/11) of patients never relapsed during follow-up period. CONCLUSIONS: Efficacy and medium-term safety of rituximab- and MMF-based protocol in managing children with MPA was evident in this study.
|
Authors | Biswanath Basu, T K S Mahapatra, Nirmal Mondal |
Journal | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
(Nephrol Dial Transplant)
Vol. 30 Suppl 1
Pg. i113-8
(Apr 2015)
ISSN: 1460-2385 [Electronic] England |
PMID | 25758433
(Publication Type: Journal Article)
|
Copyright | © The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. |
Chemical References |
- Antibodies, Antineutrophil Cytoplasmic
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Agents
- Immunosuppressive Agents
- Rituximab
- Mycophenolic Acid
|
Topics |
- Algorithms
- Antibodies, Antineutrophil Cytoplasmic
(immunology)
- Antibodies, Monoclonal, Murine-Derived
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Child
- Child, Preschool
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Glomerular Filtration Rate
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Kidney Diseases
(mortality, prevention & control)
- Male
- Microscopic Polyangiitis
(drug therapy, mortality, pathology)
- Mycophenolic Acid
(analogs & derivatives, therapeutic use)
- Remission Induction
- Retrospective Studies
- Rituximab
- Survival Rate
- Treatment Outcome
|